To include your compound in the COVID-19 Resource Center, submit it here.

CB-5083: Phase I started

Cleave began a 2-stage, open-label, U.S. Phase I trial of oral CB-5083 in up to 60

Read the full 165 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE